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Abstract
Nordic Immunohistochemical Quality Control (NordiQC) performs proficiency testing for about 600
pathology laboratories in more than 50 countries. All general results are published on
http://www.nordiqc.org. Over-all, about 30% of the staining results on circulated slides from tissue
micro arrays have been assessed as insufficient for diagnostic use by an expert group. This paper
describes the results from the two latest NordiQC runs for CD31. Out of 476 stains submitted,
30.5% were considered insufficient, mostly due to too weak or false negative staining reactions. The
best results were obtained by use of mouse monoclonal antibody JC70A with an optimized protocol
based on efficient heat induced epitope retrieval and a three-step polymer/multimer conjugate as
visualization system. The mouse monoclonal antibody 1A10 gave unsatisfactory results in almost all
cases.
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Introduction
CD31 is a transmembrane glycoprotein, about 130
kDa, also designated platelet-endothelium cell
adhesion molecule (PECAM-1), belonging to the
immunoglobulin super family and encoded by the
PECAM-1 gene on chromosome 17 [1]. CD31
expression is restricted to endothelial cells (ECs),
platelets and immune cells, suggesting that CD31
is specifically involved in the immune responses
at the vascular wall [2]. Thus, during inflammation
CD31 plays a major role in the adhesion cascade
between endothelial cells and inflammatory cells,
facilitating leucocyte migration, particularly being
an important component in the regulation of
neutrophil transendothelial migration [3]. CD31 also
plays a role in thrombosis and angiogenesis.
Immunohistochemically, CD31 is usually strongly
expressed in both blood vessel and lymphatic
vessel ECs, in a distinct membranous pattern as
it makes up a large portion of the intercellular
junctions. In liver, the expression in ECs is lower
[4] but increases with capillarization of the liver
sinusoids in chronic liver diseases [5]. CD31 is
varyingly expressed in myeloid progenitor cells,
megakaryocytes, platelets, and neutrophil
granulocytes as well as in subpopulations of B- and
T-lymphocytes. Typically, mantle zone B-cells have
a low expression of CD31, while plasma cells are
high expressors. Among neoplasms, CD31 is
expressed in the vast majority of vascular lesions,
such as haemangioma, angiofibroma, and
angiosarcoma, and in most cases of Kaposi sarcoma
and epithelioid hemangioendothelioma [6]. In some
tumours such as littoral cell angioma, identification
of CD31 may be mandatory for a correct diagnosis.
CD31 may also be expressed in a minority of
haematolymphoid neoplasms like histiocytosis,
juvenile xanthogranuloma, B- and T-cell
lymphomas, plasmacytoma, and myeloid
leukaemia. Among carcinomas and mesotheliomas,
also a minority of cases has been reported to
express CD31 [7]. CD31 assays are mostly applied
in order to identify vascular ECs in various lesions
(e.g., to visualize metastatic spread in lymphatic
and blood vessels), assess angiogenesis (vascular
density) in neoplasms and verify endothelial
neoplasms. For these purposes, CD31 is often used
in panels, which also may include other endothelial
markers like ERG, CD34, Fli-1 and Podoplanin
(D2-40)[8].
In the Nordic immunohistochemical Quality Control
(NordiQC) external quality assessment (EQA)
program, CD31 IHC assays have been assessed five
times during 2004-2016. A large proportion of
submitted assays has been assessed as insufficient
(24-48%). The aim of the present paper is to give an
overview of the CD31 EQA results in the two latest
assessments, run 38 (2013) and run 46 (2016).
Detailed assessment reports from all runs are
available on the NordiQC homepage
(http://www.nordiqc.org).
Materials and Methods
Tissue microarrays (TMAs) for the CD31 tests were
constructed for each run comprising tissues from
appendix, tonsil, liver, angiosarcoma, and (in run
46) colon adenocarcinoma. The included tissues
were all fixed in 10% neutral buffered formalin for
24-48 hours. Criteria for assessing CD31 staining as
optimal included:
• A strong and distinct, predominantly membranous
staining reaction of virtually all normal ECs and
plasma cells in appendix and tonsil
• An at least weak to moderate, distinct
membranous staining reaction of activated B- and
T-cells, in particular mantle zone B-cells, in the
tonsil and intraepithelial T-cells in the appendix
• An at least weak to moderate staining reaction of
the majority of the hepatic sinusoidal ECs
• An at least moderate, predominantly
membranous staining reaction of the vast majority
of neoplastic cells in the angiosarcoma
• No staining reaction of epithelial cells.
Sections from different levels of the TMAs were
stained for CD31 in the NordiQC reference
laboratory (Lab) using mmAb clone JC70A to ensure
an appropriate and constant expression of CD31
throughout the slides to be circulated. Participants
submitted their CD31 IHC staining protocols on the
NordiQC homepage and received a pair of slides cut
from the test TMAs. The participants performed the
IHC assays for CD31 according to their submitted
protocol and returned one of the slides to NordiQC.
An expert assessor panel consisting of experienced
pathologists and technicians performed the
assessment. The assessor panel performed an
anonymized consensus assessment by evaluating
each slide on a microscope linked to a projector.
Each assay was marked as “optimal,” “good,”
“borderline,” or “poor” based on the technical
quality and concordance to the staining pattern as
outlined above. Optimal and good are considered
sufficient, while borderline and poor are insufficient
for diagnostic use.
Results
In the two runs (38/2013 and 46/2016), a total of
476 slides stained for CD31 were assessed (Table
1). The most commonly used antibody (Ab) was
mouse monoclonal (mm) Ab clone JC70A applied
in 257 cases, of which 73.9% provided a sufficient
result (optimal or good). Optimal staining results
could be obtained on all main platforms (Dako,
Leica and Ventana). Among the Lab developed tests
(LDTs), the highest proportion of optimal results was
obtained by efficient heat induced epitope retrieval
(HIER) in an alkaline buffer, TRS low pH (Dako) or
DIVA pH 6 (Biocare), in combination with an
appropriate calibration of the primary Ab and use of
a sensitive 3-step detection system.
Table 1
Pooled staining results related to antibodies in the two latest runs assessed by
NordiQC.
Clone and format No. of slides Optimal (%) Good (%) Insufficient (%)
JC70A Conc 257 43.6 30.3 26.1
JC70A RTU Dako 100 57.0 35.0 8.0
JC70A RTU Ventana 82 30.5* 20.7 48.8
1A10 RTU Leica 10 0.0 0.0 100.0
1A10 Conc 9 0.0 11.1 88.9
Other 18 16.7 16.7 66.7
Total 476 41.4 28.2 30.5
*Optimal results could only be obtained by modifying the vendor protocol recommendations.
Conc: Concentrate, RTU: Ready to use
The mmAb clone JC70A in a ready to use (RTU)
product from six vendors was used in 189 cases,
of which 73.0% provided a sufficient result. The
RTU products from Dako used in 100 cases gave
sufficient results in 92.0%, of which 57% were
optimal. An optimal result could both be obtained
by the Dako recommended protocol settings and
by Lab modified settings. The RTU product from
Ventana used in 82 cases gave sufficient results in
51.2% and only 30.5% being optimal. An optimal
result with the Ventana product was typically based
on a Lab modified protocol using a 3-step detection
system as OptiView or UltraView + amplification.
In contrast, adherence to the vendor recommended
protocol settings, which includes the 2-step
visualization system Ultraview, could not provide
any optimal staining reaction.
Only few participants used other antibodies than
mmAb clone JC70A. The mmAb clone 1A10 was
applied in 20 cases either as a concentrate (Conc)
or an RTU product. However, none were optimal,
only one was good, and 19 (95%) were insufficient.
Nine slides were stained for CD31 using one of the
clones EP3095, UC-CD31, BS50 or EP78 as a Conc or
BC2 as an RTU product. None of these provided an
optimal result and only BC2 gave good results (both
of two stains).
The prevalent feature of insufficient staining results
was a “too weak” or “false negative” staining
reaction in cells and structures expected to be
demonstrated (Figure 1). These patterns were
observed in 98% of the insufficient results. Virtually
all Labs were able to demonstrate CD31 in high
level antigen expressing structures such as ECs of
the large vessels in the appendix and portal tracts
of the liver, whereas demonstration of CD31 in low
level expressing structures as hepatic sinusoidal
ECs and activated B-cells in the mantle zones of the
tonsil were more challenging.
Figure 1: Optimal and insufficient staining results for CD31 as assessed by NordiQC.
Discussion and Conclusion
In the NordiQC EQA, about 30% of all stains in the
general module have been assessed as insufficient
for diagnostic use [9]. About 90% of insufficient
results are characterized by a “too weak” or “false
negative” reaction, particularly in cells with a low
epitope expression. In most cases, the major causes
can be identified as less successful (poor and less
robust) antibodies, poorly calibrated RTU products,
stainer platform-dependent antibodies,
insufficiently calibrated antibody dilutions,
insufficient/erroneous epitope retrieval, less
sensitive visualization systems, and others (e.g.,
retrieval induced impaired morphology, drying out
phenomena, stainer platform-dependent protocol
issues, platforms causing uneven staining
reactions).
In the current EQA of CD31 assays, the less
successful mmAb clone 1A10 and low sensitivity
protocols were prevailing causes of insufficient
staining results. Also a significant cause may be
the lack of awareness of the immunohistochemical
critical assay performance controls (iCAPCs) as it
is essential to demonstrate an appropriate and
successful level of the analytical sensitivity in the
assay for CD31. Liver, tonsil and appendix
combined are appropriate as positive and negative
control tissues for CD3. In tonsil virtually all plasma
cells and ECs lining large vessels should show a
moderate to strong staining reaction, whereas the
vast majority of mantle zone B-cells must show
an at least weak to moderate staining reaction.
The positive staining reaction of mantle zone B-
cells with low-level CD31 expression serves as the
iCAPC for the low limit of detection of CD31. In
liver, the hepatic sinusoidal ECs are also suitable as
iCAPC for CD31, due to low-level CD31 expression.
No staining reaction should be seen in e.g.,
hepatocytes, appendiceal columnar epithelial cells
and squamous epithelial cells in tonsil, all serving
as negative tissue controls.
Also in this context, it has to be emphasized that
these tissue controls should be used together as
external on-slide control to confirm the IHC test
Figure 1: Optimal and insufficient staining results for CD31 as assessed by NordiQC.
A. Optimal CD31 staining of the liver using the mmAb clone JC70A as a concentrate, HIER in an
alkaline buffer and a 3-step multimer based detection system. Virtually all the hepatic sinusoidal
endothelial cells show a weak to moderate, predominantly membranous staining reaction.
B. Same field as in A. Insufficient staining for CD31 of the liver using the mmAb clone JC70A in a
protocol with a too low sensitivity. Endothelial cells lining large vessels are demonstrated, while
the sinusoidal endothelial cells are false negative.
C. Optimal CD31 staining of the tonsil using the mmAb clone JC70A in an RTU format (GA610,
Dako), with HIER in TRS High pH 9 for 30 min., a 3-step polymer-based detection kit, performed
on the Dako Omnis stainer (vendor recommended protocol settings). Even at low magnification a
distinct positive staining reaction of mantle zone B-cells, plasma cells and endothelial cells can be
identified.
D. Same field as in C. Insufficient CD31 staining of the tonsil using the mmAb clone JC70A in
an RTU format (IR610, Dako) but with laboratory modified protocol settings reducing HIER time
and changing detection kit. The endothelial cells are weakly stained, the lymphocytes are false
negative. E. Higher magnification of the tonsil in C. A moderate and distinct membranous staining
reaction is seen in the majority of mantle zone B-cells, while plasma cells and endothelial cells
show an intense staining reaction.
F. Same field as in E, same protocol as in D. Insufficient CD31 staining of the tonsil. Only
endothelial cells and plasma cells are demonstrated, while mantle zone B-cells are negative.
G. Optimal CD31 staining of the angiosarcoma using the same protocol as in C and E. Virtually all
neoplastic cells show a distinct, predominantly membranous staining reaction.
H. Same field as in G, same antibody and protocol as in D and F. Insufficient CD31 staining of
the angiosarcoma. The intensity and proportion of neoplastic cells demonstrated is significantly
reduced compared to G. CD31 positive normal endothelial cells are demonstrated (top left)
emphasizing that these cells cannot reliably be used as internal positive tissue control.
Foot note: All photos in the multi-panel are obtained by Hamamatsu Nano Zoomer 2.0-RS slide
scanner at 20X (A-B, E-H) or 4X (C-D) magnification.
reproducibility. Batch controls and internal controls
(ECs in general) for CD31 cannot stand alone as in
most instances they do not accurately monitor and
assure the IHC analytical test performance [10].
In conclusion, the key points for CD31
immunoassays are as follows:
• Select a sensitive Ab clone, e.g., mmAb JC70A as
Conc in an LDT or in a Dako/Agilent RTU format
• Do not use an insensitive clone like mmAb clone
1A10
• Use an optimized protocol based on HIER and a
three-step polymer/multimer conjugate
• Use appropriate on-slide iCAPCs for CD31 (Liver,
tonsil and appendix).
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